G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome

World Journal of Hepatology

Volumn 4, Issue 4, 2012, Pages 129-138

  Czegle, Ibolya ^a,b   Csala, Miklós ^c   Mandl, József ^b,c   Benedetti, Angelo ^d   Karádi, István ^a   Bánhegyi, Gábor ^c,d  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Metabolic syndrome Liver Glucocorticoid Glucose 6 phosphate transporter Hexose 6 phosphate dehydrogenase 11 hydroxysteroid dehydrogenase type 1

Indexed keywords

EID: 84885846436     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v4.i4.129     Document Type: Review

References (85)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553
2. WHO Consultation. Definition, diagnosis and classification of diabetes melllitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organisation, Geneva; 1999. Report No. 99.2. Available from: URL: http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf
3. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) Diabet Med 1999; 16: 442-443
4. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report). NIH Publication, 2001: No. 01-3670
5. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation. 2005. Available from: URL: http://www.idf.org/idf-worldwide-definitionmetabolic-syndrome
6. The IDF consensus worldwide definition of the metabolic syndrome. 2006. Diabetes Atlas, third edition. International Diabetes Federation 2006, Brussel. Available from: URL: http://www.idf.org/webdata/docs/MetS_def_update2006.pdf. Accessed March 2007
7. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone > cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999; 84: 1022-1027
8. Shimomura Y, Bray GA, Lee M. Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res 1987; 19: 295-299
9. Hewitt KN, Walker EA, Stewart PM. Minireview: hexose- 6-phosphate dehydrogenase and redox control of 11{beta}- hydroxysteroid dehydrogenase type 1 activity. Endocrinology 2005; 146: 2539-2543
10. Atanasov AG, Nashev LG, Gelman L, Legeza B, Sack R, Portmann R, Odermatt A. Direct protein-protein interaction of 11beta-hydroxysteroid dehydrogenase type 1 and hexose- 6-phosphate dehydrogenase in the endoplasmic reticulum lumen. Biochim Biophys Acta 2008; 1783: 1536-1543
11. Bánhegyi G, Benedetti A, Fulceri R, Senesi S. Cooperativity between 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the lumen of the endoplasmic reticulum. J Biol Chem 2004; 279: 27017-27021
12. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CH, Stewart PM. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003; 34: 434-439
13. Piccirella S, Czegle I, Lizák B, Margittai E, Senesi S, PappE, Csala M, Fulceri R, Csermely P, Mandl J, Benedetti A, Bánhegyi G. Uncoupled redox systems in the lumen of the endoplasmic reticulum. Pyridine nucleotides stay reduced in an oxidative environment. J Biol Chem 2006; 281: 4671-4677
14. Czegle I, Piccirella S, Senesi S, Csala M, Mandl J, Bánhegyi G, Fulceri R, Benedetti A. Cooperativity between 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase is based on a common pyridine nucleotide pool in the lumen of the endoplasmic reticulum. Mol Cell Endocrinol 2006; 248: 24-25
15. Bánhegyi G, Csala M, Benedetti A. Hexose-6-phosphate dehydrogenase: linking endocrinology and metabolism in the endoplasmic reticulum. J Mol Endocrinol 2009; 42: 283-289
16. Mandl J, Mészáros T, Bánhegyi G, Hunyady L, Csala M. Endoplasmic reticulum: nutrient sensor in physiology and pathology. Trends Endocrinol Metab 2009; 20: 194-201
17. Leuzzi R, Bánhegyi G, Kardon T, Marcolongo P, Capecchi PL, Burger HJ, Benedetti A, Fulceri R. Inhibition of microsomal glucose-6-phosphate transport in human neutrophils results in apoptosis: a potential explanation for neutrophil dysfunction in glycogen storage disease type 1b. Blood 2003; 101: 2381-2387
18. Belkaid A, Copland IB, Massillon D, Annabi B. Silencing of the human microsomal glucose-6-phosphate translocase induces glioma cell death: potential new anticancer target for curcumin. FEBS Lett 2006; 580: 3746-3752
19. Kardon T, Senesi S, Marcolongo P, Legeza B, Bánhegyi G, Mandl J, Fulceri R, Benedetti A. Maintenance of luminal NADPH in the endoplasmic reticulum promotes the survival of human neutrophil granulocytes. FEBS Lett 2008; 582: 1809-1815
20. Lavery GG, Walker EA, Turan N, Rogoff D, Ryder JW, Shelton JM, Richardson JA, Falciani F, White PC, Stewart PM, Parker KL, McMillan DR. Deletion of hexose-6-phosphate dehydrogenase activates the unfolded protein response pathway and induces skeletal myopathy. J Biol Chem 2008; 283: 8453-8461
21. Marcolongo P, Piccirella S, Senesi S, Wunderlich L, Gerin I, Mandl J, Fulceri R, Bánhegyi G, Benedetti A. The glucose- 6-phosphate transporter-hexose-6-phosphate dehydrogenase- 11beta-hydroxysteroid dehydrogenase type 1 system of the adipose tissue. Endocrinology 2007; 148: 2487-2495
22. Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 2001; 15: 61-78
23. Shimojo M, Ricketts ML, Petrelli MD, Moradi P, Johnson GD, Bradwell AR, Hewison M, Howie AJ, Stewart PM. Immunodetection of 11 beta-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization. Endocrinology 1997; 138: 1305-1311
24. Stewart PM. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrinol 2003; 149: 163-168
25. Basu R, Basu A, Grudzien M, Jung P, Jacobson P, Johnson M, Singh R, Sarr M, Rizza RA. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 2009; 58: 39-45
26. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997; 349: 1210-1213
27. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology 1999; 140: 3188-3196
28. Bujalska IJ, Walker EA, Hewison M, Stewart PM. A switch in dehydrogenase to reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002; 87: 1205-1210
29. Nashev LG, Chandsawangbhuwana C, Balazs Z, Atanasov AG, Dick B, Frey FJ, Baker ME, Odermatt A. Hexose-6- phosphate dehydrogenase modulates 11beta-hydroxysteroid dehydrogenase type 1-dependent metabolism of 7-keto- and 7beta-hydroxy-neurosteroids. PLoS One 2007; 2: e561
30. Bujalska IJ, Draper N, Michailidou Z, Tomlinson JW, White PC, Chapman KE, Walker EA, Stewart PM. Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1. J Mol Endocrinol 2005; 34: 675-684
31. Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R, Pfeiffer EF. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 1989; 84: 1663-1670
32. Atanasov AG, Nashev LG, Schweizer RA, Frick C, Odermatt A. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett 2004; 571: 129-133
33. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170
34. Napolitano A, Voice MW, Edwards CR, Seckl JR, Chapman KE. 11Beta-hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent and hormonally regulated. J Steroid Biochem Mol Biol 1998; 64: 251-260
35. Jessen BA, Stevens GJ. Expression profiling during adipocyte differentiation of 3T3- L1 fibroblasts. Gene 2002; 299: 95-100
36. Senesi S, Marcolongo P, Manini I, Fulceri R, Sorrentino V, Csala M, Bánhegyi G, Benedetti A. Constant expression of hexose-6-phosphate dehydrogenase during differentiation of human adipose-derived mesenchymal stem cells. J Mol Endocrinol 2008; 41: 125-133
37. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 2008; 197: 189-204
38. Ricketts ML, Shoesmith KJ, Hewison M, Strain A, Eggo MC, Stewart PM. Regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J Endocrinol 1998; 156: 159-168
39. Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11 betahydroxysteroid dehydrogenase is an exclusive 11 betareductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995; 136: 4754-4761
40. Jamieson PM, Walker BR, Chapman KE, Andrew R, Rossiter S, Seckl JR. 11 beta-hydroxysteroid dehydrogenase type 1 is a predominant 11 beta-reductase in the intact perfused rat liver. J Endocrinol 2000; 165: 685-692
41. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 1997; 94: 14924-14929
42. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC. Intracellular regeneration of glucocorticoids by 11betahydroxysteroid dehydrogenase (11beta-HSD)- 1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice. Endocrinology 2001; 142: 114-120
43. Alberts P, Engblom L, Edling N, Forsgren M, Klingström G, Larsson C, Rönquist-Nii Y, Ohman B, Abrahmsén L. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002; 45: 1528-1532
44. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingström G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Björkstrand E, Abrahmsen LB. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003; 144: 4755-4762
45. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112: 83-90
46. Livingstone DE, Kenyon CJ, Walker BR. Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 2000; 167: 533-539
47. Mattsson C, Lai M, Noble J, McKinney E, Yau JL, Seckl JR, Walker BR. Obese Zucker rats have reduced mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 1 expression in hippocampus-implications for dysregulation of the hypothalamic-pituitary-adrenal axis in obesity. Endocrinology 2003; 144: 2997-3003
48. Liu Y, Nakagawa Y, Wang Y, Li R, Li X, Ohzeki T, Friedman TC. Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes 2003; 52: 1409-1416
49. Liu Y, Nakagawa Y, Wang Y, Sakurai R, Tripathi PV, Lutfy K, Friedman TC. Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice. Diabetes 2005; 54: 32-40
50. Morton NM, Densmore V, Wamil M, Ramage L, Nichol K, Bünger L, Seckl JR, Kenyon CJ. A polygenic model of the metabolic syndrome with reduced circulating and intraadipose glucocorticoid action. Diabetes 2005; 54: 3371-3378
51. Zemanova Z, Strnadova M, Jirsova Z, Klusonova P. Occurrence of lipids in the liver of the hypertriglyceridemic rats. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153: 37-39
52. Berthiaume M, Laplante M, Festuccia WT, Cianflone K, Turcotte LP, Joanisse DR, Olivecrona G, Thieringer R, Deshaies Y. 11beta- HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab 2007; 293: E1045-E1052
53. Nuotio-Antar AM, Hachey DL, Hasty AH. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab 2007; 293: E1517-E1528
54. Wamil M, Seckl JR. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 2007; 12: 504-520
55. Rask E, Walker BR, Söderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002; 87: 3330-3336
56. Andrew R, Phillips DI, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998; 83: 1806-1809
57. Tiosano D, Eisentein I, Militianu D, Chrousos GP, Hochberg Z. 11 beta-Hydroxysteroid dehydrogenase activity in hypothalamic obesity. J Clin Endocrinol Metab 2003; 88: 379-384
58. Rask E, Olsson T, Söderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-1421
59. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999; 33: 1364-1368
60. Csábi GY, Juricskay S, Molnár D. Urinary cortisol to cortisone metabolites in hypertensive obese children. J Endocrinol Invest 2000; 23: 435-439
61. Reynolds RM, Walker BR, Syddall HE, Andrew R, Wood PJ, Whorwood CB, Phillips DI. Altered control of cortisol secretion in adult men with low birth weight and cardiovascular risk factors. J Clin Endocrinol Metab 2001; 86: 245-250
62. Duclos M, Marquez Pereira P, Barat P, Gatta B, Roger P. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res 2005; 13: 1157-1166
63. Simonyte K, Rask E, Näslund I, Angelhed JE, Lönn L, Olsson T, Mattsson C. Obesity is accompanied by disturbances in peripheral glucocorticoid metabolism and changes in FA recycling. Obesity (Silver Spring) 2009; 17: 1982-1987
64. Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH, Stewart PM, Kumar S. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 4755-4761
65. Low SC, Chapman KE, Edwards CR, Seckl JR. 'Liver-type' 11 beta-hydroxysteroid dehydrogenase cDNA encodes reductase but not dehydrogenase activity in intact mammalian COS- 7 cells. J Mol Endocrinol 1994; 13: 167-174
66. Low SC, Chapman KE, Edwards CR, Wells T, Robinson IC, Seckl JR. Sexual dimorphism of hepatic 11 beta-hydroxysteroid dehydrogenase in the rat: the role of growth hormone patterns. J Endocrinol 1994; 143: 541-548
67. Voice MW, Seckl JR, Edwards CR, Chapman KE. 11 beta-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism. Biochem J 1996; 317 (Pt 2): 621-625
68. Iwasaki Y, Takayasu S, Nishiyama M, Tsugita M, Taguchi T, Asai M, Yoshida M, Kambayashi M, Hashimoto K. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11betahydroxysteroid dehydrogenase type 1) gene. Mol Cell Endocrinol 2008; 285: 10-18
69. Ignatova ID, Kostadinova RM, Goldring CE, Nawrocki AR, Frey FJ, Frey BM. Tumor necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-beta in HepG2 cells. Am J Physiol Endocrinol Metab 2009; 296: E367-E377
70. Williams LJ, Lyons V, MacLeod I, Rajan V, Darlington GJ, Poli V, Seckl JR, Chapman KE. C/EBP regulates hepatic transcription of 11beta -hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J Biol Chem 2000; 275: 30232-30239
71. Whorwood CB, Sheppard MC, Stewart PM. Tissue specific effects of thyroid hormone on 11 beta-hydroxysteroid dehydrogenase gene expression. J Steroid Biochem Mol Biol 1993; 46: 539-547
72. Zumoff B, Bradlow HL, Levin J, Fukushima DK. Influence of thyroid function on the in vivo cortisol in equilibrium cortisone equilibrium in man. J Steroid Biochem 1983; 18: 437-440
73. Sampath-Kumar R, Yu M, Khalil MW, Yang K. Metyrapone is a competitive inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 reductase. J Steroid Biochem Mol Biol 1997; 62: 195-199
74. Stewart PM, Burra P, Shackleton CH, Sheppard MC, Elias E. 11 beta-Hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and nonalcoholic chronic liver disease. J Clin Endocrinol Metab 1993; 76: 748-751
75. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005; 54: 872-879
76. Livingstone DE, Walker BR. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 2003; 305: 167-172
77. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995; 80: 3155-3159
78. Tomlinson JW, Sherlock M, Hughes B, Hughes SV, Kilvington F, Bartlett W, Courtney R, Rejto P, Carley W, Stewart PM. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 2007; 92: 857-864
79. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R. 11beta- HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005; 202: 517-527
80. Barf T, Vallgårda J, Emond R, Häggström C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L, Edling N, Rönquist-Nii Y, Ohman B, Alberts P, Abrahmsén L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2002; 45: 3813-3815
81. London E, Lala G, Berger R, Panzenbeck A, Kohli AA, Renner M, Jackson A, Raynor T, Loya K, Castonguay TW. Sucrose access differentially modifies 11beta-hydroxysteroid dehydrogenase- 1 and hexose-6-phosphate dehydrogenase message in liver and adipose tissue in rats. J Nutr 2007; 137: 2616-2621
82. Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, Shackleton CH, Parker KL, White PC, Stewart PM. Hexose- 6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 2006; 281: 6546-6551
83. Rogoff D, Ryder JW, Black K, Yan Z, Burgess SC, McMillan DR, White PC. Abnormalities of glucose homeostasis and the hypothalamic-pituitary-adrenal axis in mice lacking hexose-6-phosphate dehydrogenase. Endocrinology 2007; 148: 5072-5080
84. Lavery GG, Hauton D, Hewitt KN, Brice SM, Sherlock M, Walker EA, Stewart PM. Hypoglycemia with enhanced hepatic glycogen synthesis in recombinant mice lacking hexose-6-phosphate dehydrogenase. Endocrinology 2007; 148: 6100-6106
85. Walker EA, Ahmed A, Lavery GG, Tomlinson JW, Kim SY, Cooper MS, Ride JP, Hughes BA, Shackleton CH, McKiernan P, Elias E, Chou JY, Stewart PM. 11beta-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function. J Biol Chem 2007; 282: 27030-27036